Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Mereo BioPharma (MREO) over the last 6 years, with Q3 2025 value amounting to $6.0 million.

  • Mereo BioPharma's Total Current Liabilities fell 5765.77% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 5765.77%. This contributed to the annual value of $13.8 million for FY2024, which is 4598.36% up from last year.
  • Latest data reveals that Mereo BioPharma reported Total Current Liabilities of $6.0 million as of Q3 2025, which was down 5765.77% from $7.6 million recorded in Q2 2025.
  • Mereo BioPharma's 5-year Total Current Liabilities high stood at $44.3 million for Q2 2022, and its period low was $6.0 million during Q3 2025.
  • Over the past 5 years, Mereo BioPharma's median Total Current Liabilities value was $13.8 million (recorded in 2021), while the average stood at $14.6 million.
  • In the last 5 years, Mereo BioPharma's Total Current Liabilities skyrocketed by 22131.81% in 2022 and then tumbled by 5765.77% in 2025.
  • Mereo BioPharma's Total Current Liabilities (Quarter) stood at $16.9 million in 2021, then soared by 162.26% to $44.3 million in 2022, then tumbled by 78.6% to $9.5 million in 2023, then soared by 45.98% to $13.8 million in 2024, then plummeted by 56.56% to $6.0 million in 2025.
  • Its last three reported values are $6.0 million in Q3 2025, $7.6 million for Q2 2025, and $7.5 million during Q1 2025.